Search

Displaying results 2561 - 2570 of 8575 in total
  1. Drug

    Palopegteriparatide

    go.drugbank.com/drugs/DB18676
    ApprovedInvestigational

    [L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.

  2. Drug

    Pipecuronium

    go.drugbank.com/drugs/DB01338
    ApprovedInvestigationalWithdrawn

    Pipecuronium is a piperazinyl androstane derivative which is a non-depolarizing neuromuscular blocking agent.

  3. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed … [A244470,A244499] Sotagliflozin was approved by the EMA under the brand name "Zynquista" on April 26, 2019, for the treatment of type 1 diabetes.

  4. Drug

    Alclometasone

    go.drugbank.com/drugs/DB00240
    Approved

    Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.

  5. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    The prevalence of neurotrophic keratitis has been estimated to be less than five in 10,000 individuals. … The approval of cenegermin consequently provides a novel topical treatment that has the potential capacity to offer total corneal healing for many patients who may use the agent.

  6. Drug

    13-deoxydoxorubicin

    go.drugbank.com/drugs/DB05706
    Investigational

    GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.

  7. Drug

    Levocetirizine

    go.drugbank.com/drugs/DB06282
    ApprovedInvestigational

    [L7694] Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]

  8. Drug

    Remifentanil

    go.drugbank.com/drugs/DB00899
    ApprovedInvestigational

    Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic.

  9. Drug

    Dimethyltryptamine

    go.drugbank.com/drugs/DB01488
    IllicitInvestigational

    It apparently acts as an agonist at some types of serotonin receptors and an antagonist at others.

  10. Drug

    L-Glutamine

    go.drugbank.com/drugs/DB00130
    ApprovedInvestigationalNutraceutical

    An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.